[CAS NO. 97-59-6]  Allantoin

The subchronic administration of allantoin (1, 3 or 10 mg/kg, for 7 days) significantly increases the latency time measured during the passive avoidance task in scopolamine-induced cholinergic blockade and normal naive mice. Allantoin treatment (3 or 10 mg/kg, for 7 days) also increases the expression levels of phosphorylated phosphatidylinositide 3-kinase (PI3K), phosphorylated protein kinase B (Akt) and phosphorylated glycogen synthase kinase-3β (GSK-3β). Allantoin significantly increases the neuronal cell proliferation of immature neurons in the hippocampal dentate gyrus region ^[1] . Daily injection of allantoin for 8 days in STZ-treated rats significantly lowers plasma glucose and increases plasma insulin levels ^[2] . Allantoin decreases blood pressures in SHRs at 30 minutes, as the most effective time. Also, this antihypertensive action is shown in a dose-dependent manner from SHRs treated with allantoin. Moreover, in anesthetized rats, allantoin inhibits cardiac contractility and heart rate. Also, the peripheral blood flow is markedly increased by allantoin ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.